Day : Wednesday

Date: 3/28/2007
Time: 08:37:33

PALM INTRANET

Inventor Information for 10/828795

Inventor Name	City	State/Country
WEBER, ECKARD	SAN DIEGO	CALIFORNIA
COWLEY, MICHAEL ALEXANDER	PORTLAND	OREGON

Appln Info | Contents | Petition Info | Atty/Agent Info | Continuity/Reexam | Foreign D

Search Another: Application# [ ] Search **or Patent#** [ ] Search

PCT / [ ] / [ ] Search **or PG PUBS #** [ ] Search

Attorney Docket # [ ] Search

Bar Code # [ ] Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

```
     (FILE 'HOME' ENTERED AT 09:11:35 ON 28 MAR 2007)

     FILE 'REGISTRY' ENTERED AT 09:11:46 ON 28 MAR 2007
L1           191 S NALTREXONE
L2             0 S NALTREXONE/CT
L3             1 S NALTREXONE/CN
L4             1 S BUPROPION/CN

     FILE 'CAPLUS' ENTERED AT 09:12:22 ON 28 MAR 2007

     FILE 'REGISTRY' ENTERED AT 09:12:31 ON 28 MAR 2007
                SET SMARTSELECT ON
L5           SEL L3 1- CHEM :      12 TERMS
                SET SMARTSELECT OFF

     FILE 'CAPLUS' ENTERED AT 09:12:31 ON 28 MAR 2007
L6          4022 S L5
L7          4022 S L6 OR NALTREXONE?

     FILE 'REGISTRY' ENTERED AT 09:12:56 ON 28 MAR 2007
                SET SMARTSELECT ON
L8           SEL L4 1- CHEM :       8 TERMS
                SET SMARTSELECT OFF

     FILE 'CAPLUS' ENTERED AT 09:12:57 ON 28 MAR 2007
L9          1392 S L8
L10         1394 S L9 OR BUPROPION?
L11         1392 S L9 AND L10
L12           51 S L10 AND L7
L13            5 S L12 AND (EXTENDED? OR CONTROLLED OR SLOW RELEASE OR LONG ACTI
L14            5 FOCUS L13 1-

     FILE 'USPATFULL' ENTERED AT 09:16:47 ON 28 MAR 2007

=> s l12
REFERENCED SmartSELECT L-NUMBERS CAN NOT BE SEARCHED
SmartSELECT L-numbers may be combined with other logic in the same
search when entered at the level one prompt.  Referenced SmartSELECT
L-numbers can not be searched when combined with additional terms.
This can occur when searching an L-number answer set in a file other
than where it was created.

=> s l3 and l4
           365 L3
           320 L4
L15         21 L3 AND L4

=> s l15 and (extended? or controlled or slow release or long acting or
slow-released or long-acting)
        824870 EXTENDED?
       1629411 CONTROLLED
             1 CONTROLLEDS
       1629411 CONTROLLED
                 (CONTROLLED OR CONTROLLEDS)
        421531 SLOW
         42040 SLOWS
        446283 SLOW
                 (SLOW OR SLOWS)
        713004 RELEASE
        169635 RELEASES
        774036 RELEASE
                 (RELEASE OR RELEASES)
         20352 SLOW RELEASE
```

```
                (SLOW(W)RELEASE)
        1782009 LONG
            522 LONGS
        1782102 LONG
                (LONG OR LONGS)
         507890 ACTING
             12 ACTINGS
         507897 ACTING
                (ACTING OR ACTINGS)
           9354 LONG ACTING
                (LONG(W)ACTING)
         421531 SLOW
          42040 SLOWS
         446283 SLOW
                (SLOW OR SLOWS)
         594894 RELEASED
             71 SLOW-RELEASED
                (SLOW(W)RELEASED)
        1782009 LONG
            522 LONGS
        1782102 LONG
                (LONG OR LONGS)
         507890 ACTING
             12 ACTINGS
         507897 ACTING
                (ACTING OR ACTINGS)
           9354 LONG-ACTING
                (LONG(W)ACTING)
L16          17 L15 AND (EXTENDED? OR CONTROLLED OR SLOW RELEASE OR LONG ACTING
                OR SLOW-RELEASED OR LONG-ACTING)

=> focus
PROCESSING COMPLETED FOR L16
L17          17 FOCUS L16 1-

=> d ibib abs hitstr 1-17

L17  ANSWER 1 OF 17  USPATFULL on STN
ACCESSION NUMBER:        2003:207910  USPATFULL
TITLE:                   Methods for the treatment of substance abuse
INVENTOR(S):             Shulman, Albert, Victoria, AUSTRALIA

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2003144271      A1   20030731
APPLICATION INFO.:       US 2002-181990     A1   20021106  (10)
                         WO 2001-AU60            20010122

                               NUMBER         DATE
                         ------------------ --------
PRIORITY INFORMATION:    GB 2000-1390       20000122
                         GB 2000-1647       20000126
                         AU 2000-2237       20001221
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET,
                         FOURTEENTH FLOOR, IRVINE, CA, 92614
NUMBER OF CLAIMS:        37
EXEMPLARY CLAIM:         1
LINE COUNT:              1593
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      The present invention relates to methods of therapy for substance
        addiction comprising the administration to a subject in need thereof a
        combination of: (i) a μ-opioid receptor antagonist; (ii) a calcium
```

channel blocker which is **long-acting** or in sustained-release form or which is nimodipine in rapid release form; and (iii) an NMDA glutamate receptor modulator; as well as combinations, kits and composition useful therefor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **16590-41-3**, Naltrexone **34911-55-2**, Bupropion
(μ opioid antagonist, calcium channel blocker, and NMDA glutamate receptor modulator for treatment of substance abuse)
RN 16590-41-3 USPATFULL
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 USPATFULL
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



L17 ANSWER 2 OF 17 USPATFULL on STN

ACCESSION NUMBER:	96:7552 USPATFULL
TITLE:	**Controlled**, sustained release delivery system for treating drug dependency
INVENTOR(S):	Kitchell, Judith P., Newton, MA, United States Muni, Indu A., N. Reading, MA, United States Boyer, Yvonne N., Salem, MA, United States
PATENT ASSIGNEE(S):	DynaGen, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5486362		19960123
APPLICATION INFO.:	US 1993-140280		19931021 (8)
DISCLAIMER DATE:	20120404		
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1992-880959, filed on 7 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-696637, filed on 7 May 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		

PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Azpuru, Carlos A.
LEGAL REPRESENTATIVE: Wolf, Greenfield & Sacks
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 1132
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A drug delivery system useful in treating an individual for a drug dependence is described. One embodiment of the system is useful for aiding individuals in the cessation of smoking or chewing nicotine containing products is described. The delivery system includes a physical constraint modulation system (PCMS.TM.) containing lobeline. The drug delivery system is capable of delivering lobeline to an individual in a **controlled**, sustained release manner and providing long-term therapeutic levels of lobeline to the individual. The delivery of lobeline in such a manner reduces or eliminates the individual's smoking or chewing habit. The PCMS may be a biodegradable polymer containing the lobeline capable of subcutaneous or intramuscular injection or implantation into the individual or may be part of a transdermal patch containing lobeline. Also described are methods of using the drug delivery systems in treating other drug dependencies and kits containing the drug delivery systems.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **34911-55-2**, Amfebutamone
(drug delivery system containing, for cocaine dependence treatment)
RN 34911-55-2 USPATFULL
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



IT **16590-41-3**, Naltrexone
(drug delivery system containing, for heroin dependence treatment)
RN 16590-41-3 USPATFULL
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 3 OF 17 USPATFULL on STN

ACCESSION NUMBER: 96:62895 USPATFULL
TITLE: **Controlled**, sustained release delivery system for smoking cessation
INVENTOR(S): Kitchell, Judith P., Newton, MA, United States
Muni, Indu A., N. Reading, MA, United States
Boyer, Yvonne N., Salem, MA, United States
PATENT ASSIGNEE(S): DynaGen, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5536503		19960716
APPLICATION INFO.:	US 1995-415859		19950403 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1993-135847, filed on 13 Oct 1993, now patented, Pat. No. US 5403595 which is a continuation of Ser. No. US 1992-881740, filed on 7 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-696637, filed on 7 May 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Azpuru, Carlos
LEGAL REPRESENTATIVE: Wolf, Greenfield & Sacks
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 946
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A drug delivery system useful in aiding individuals in the cessation of smoking or chewing nicotine containing products is described. The delivery system includes a physical constraint modulation system (PCMS.TM.) containing lobeline. The drug delivery system is capable of delivering lobeline to an individual in a **controlled**, sustained release manner and providing long-term therapeutic levels of lobeline to the individual. The delivery of lobeline in such a manner reduces or eliminates the individual's smoking or chewing habit. The PCMS may be a biodegradable polymer containing the lobeline capable of subcutaneous or intramuscular injection or implantation into the individual or may be part of a transdermal patch containing lobeline. Also described are methods of using the drug delivery systems and kits containing the drug delivery systems.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **34911-55-2**, Amfebutamone
(drug delivery system containing, for cocaine dependence treatment)
RN 34911-55-2 USPATFULL
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



IT **16590-41-3**, Naltrexone
(drug delivery system containing, for heroin dependence treatment)
RN 16590-41-3 USPATFULL
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 4 OF 17 USPATFULL on STN

ACCESSION NUMBER:	95:29402 USPATFULL
TITLE:	**Controlled**, sustained release delivery system for smoking cessation
INVENTOR(S):	Kitchell, Judith P., Newton, MA, United States Muni, Indu A., N. Reading, MA, United States Boyer, Yvonne N., Salem, MA, United States
PATENT ASSIGNEE(S):	DynaGen, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5403595		19950404
APPLICATION INFO.:	US 1993-135847		19931013 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-881740, filed on 7 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-696637, filed on 7 May 1991, now abandoned

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Page, Thurman K.
ASSISTANT EXAMINER:	Azpuru, Carlos
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks
NUMBER OF CLAIMS:	10
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT:	946

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A drug delivery system useful in aiding individuals in the cessation of smoking or chewing nicotine containing products is described. The delivery system includes a physical constraint modulation system (PCMS.TM.) containing lobeline. The drug delivery system is capable of delivering lobeline to an individual in a **controlled**, sustained release manner and providing long-term therapeutic levels of lobeline to the individual. The delivery of lobeline in such a manner reduces or eliminates the individual's smoking or chewing habit. The PCMS may be a biodegradable polymer containing the lobeline capable of subcutaneous or intramuscular injection or implantation into the individual or may be part of a transdermal patch containing lobeline. Also described are methods of using the drug delivery systems and kits containing the drug delivery systems.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **34911-55-2**, Amfebutamone
(drug delivery system containing, for cocaine dependence treatment)

RN 34911-55-2 USPATFULL

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX

NAME)



IT **16590-41-3**, Naltrexone
(drug delivery system containing, for heroin dependence treatment)
RN 16590-41-3 USPATFULL
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 5 OF 17 USPATFULL on STN

ACCESSION NUMBER:	2004:69635 USPATFULL
TITLE:	Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
INVENTOR(S):	Henriksen, Dennis B., Alleroed, DENMARK Holst, Jens J., Hellerup, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004052862	A1	20040318
	US 7186683	B2	20070306
APPLICATION INFO.:	US 2003-393524	A1	20030320 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-954304, filed on 17 Sep 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-22844	20000918
	GB 2000-29920	20001207
	US 2002-371307P	20020410 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	EDWARDS & ANGELL, LLP, P.O. BOX 9169, BOSTON, MA, 02209
NUMBER OF CLAIMS:	68
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	5 Drawing Page(s)
LINE COUNT:	3496

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods for prevention and treatment of

bone-related or nutrition-related disorders using a GLP molecule or GLP activator either alone or in combination with another therapeutic. The present invention also encompasses methods of diagnosing or monitoring the progression of a disorder. The invention also encompasses methods of monitoring the effectiveness of treatment of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **16590-41-3**, Naltrexone **34911-55-2**, Bupropion
(in GLP formulations; pharmaceutical compns. and methods for use of glucagon-like peptides (GLP) analogs in treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders)
RN 16590-41-3 USPATFULL
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 USPATFULL
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



11/356839

L17 ANSWER 6 OF 17 USPATFULL on STN

ACCESSION NUMBER:	2006:167779 USPATFULL
TITLE:	Compositions for affecting weight loss
INVENTOR(S):	Weber, Eckard, San Diego, CA, UNITED STATES Cowley, Michael Alexander, Portland, OR, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006142290	A1	20060629
APPLICATION INFO.:	US 2006-356839	A1	20060217 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-828795, filed on 21 Apr 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-466838P	20030429 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION

LEGAL REPRESENTATIVE: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614, US
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 1656
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-MSH activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **16590-41-3**, Naltrexone **34911-55-2**, Bupropion
(compns. containing opioid antagonist and melanocortin agonist for affecting weight loss)
RN 16590-41-3 USPATFULL
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 USPATFULL
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



L17 ANSWER 7 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2004:321553 USPATFULL
TITLE: Compositions for affecting weight loss
INVENTOR(S): Weber, Eckard, San Diego, CA, UNITED STATES
Cowley, Michael Alexander, Portland, OR, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004254208	A1	20041216

APPLICATION INFO.: US 2004-828795 A1 20040421 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-466838P	20030429 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 1718
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-MSH activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **16590-41-3**, Naltrexone **34911-55-2**, Bupropion
(compns. containing opioid antagonist and melanocortin agonist for affecting weight loss)
RN 16590-41-3 USPATFULL
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 USPATFULL
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



L17 ANSWER 8 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2005:221541 USPATFULL

TITLE: Azabicyclic heterocycles as cannabinoid receptor modulators

INVENTOR(S): Ewing, William R., Yardley, PA, UNITED STATES
Yu, Guixue, Princeton Junction, NJ, UNITED STATES
Ellsworth, Bruce A., Princeton, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005192278	A1	20050901
	US 7037910	B2	20060502
APPLICATION INFO.:	US 2004-15876	A1	20041217 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-531451P	20031219 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 1646

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I ##STR1## including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **16590-41-3**, Naltrexone **34911-55-2**, Bupropion
(co-drug; preparation of azabicyclic heterocycles as cannabinoid receptor modulators)

RN 16590-41-3 USPATFULL
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 USPATFULL
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



L17 ANSWER 9 OF 17 USPATFULL on STN

ACCESSION NUMBER:	2005:196967 USPATFULL
TITLE:	Azabicyclic heterocycles as cannabinoid receptor modulators
INVENTOR(S):	Yu, Guixue, Princeton Junction, NJ, UNITED STATES Ewing, William R., Yardley, PA, UNITED STATES Mikkilineni, Amarendra B., Easton, PA, UNITED STATES Pendri, Annapurna, Glastonbury, CT, UNITED STATES Ellsworth, Bruce A., Princeton, NJ, UNITED STATES Sher, Philip M., Plainsboro, NJ, UNITED STATES Gerritz, Samuel, Guilford, CT, UNITED STATES Sun, Chongqing, East Windsor, NJ, UNITED STATES Murugesan, Natesan, Princeton Junction, NJ, UNITED STATES Wu, Ximao, Princeton Junction, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005171110	A1	20050804	
APPLICATION INFO.:	US 2004-16198	A1	20041217	(11)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-531451P	20031219	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
NUMBER OF CLAIMS:	73
EXEMPLARY CLAIM:	1
LINE COUNT:	2556

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I. ##STR1## including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, m and n are described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **16590-41-3**, Naltrexone **34911-55-2**, Bupropion
(co-drug; preparation of azabicyclic heterocycles as cannabinoid receptor modulators)

RN 16590-41-3 USPATFULL

CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 USPATFULL
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



L17 ANSWER 10 OF 17 USPATFULL on STN

ACCESSION NUMBER:	2005:165956 USPATFULL
TITLE:	Azabicyclic heterocycles as cannabinoid receptor modulators
INVENTOR(S):	Yu, Guixue, Princeton Junction, NJ, UNITED STATES Ewing, William R., Yardley, PA, UNITED STATES Mikkilineni, Amarendra B., Easton, PA, UNITED STATES Pendri, Annapurna, Glastonbury, CT, UNITED STATES Sher, Philip M., Plainsboro, NJ, UNITED STATES Gerritz, Samuel, Guilford, CT, UNITED STATES Ellsworth, Bruce A., Princeton, NJ, UNITED STATES Wu, Gang, Princeton, NJ, UNITED STATES Huang, Yanting, Pennington, NJ, UNITED STATES Sun, Chongqing, East Windsor, NJ, UNITED STATES Murugesan, Natesan, Princeton Junction, NJ, UNITED STATES Gu, Zhengxiang, Princeton, NJ, UNITED STATES Wang, Ying, Princeton, NJ, UNITED STATES Sitkoff, Doree, Dresher, PA, UNITED STATES Johnson, Stephen R., Erdenheim, PA, UNITED STATES Wu, Ximao, Princeton Junction, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005143381	A1	20050630	
APPLICATION INFO.:	US 2004-16135	A1	20041217	(11)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-531451P	20031219	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
NUMBER OF CLAIMS:	73
EXEMPLARY CLAIM:	1

LINE COUNT: 5350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: ##STR1## including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R.sup.1, R.sup.2, R.sup.3, R.sup.6, R.sup.7, m and n are described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **16590-41-3**,, Naltrexone **34911-55-2**, Bupropion
(co-drug; preparation of azabicyclic heterocycles as cannabinoid receptor modulators)
RN 16590-41-3 USPATFULL
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 USPATFULL
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



L17 ANSWER 11 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2004:308298 USPATFULL
TITLE: Treatment of refractory depression with an opiate antagonist and an antidepressant
INVENTOR(S): Glover, Hillel, New York, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004242974	A1	20041202
APPLICATION INFO.:	US 2004-878285	A1	20040629 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-925190, filed on 9 Aug 2001, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DICKSTEIN SHAPIRO MORIN & OSHINSKY LLP, 2101 L STREET

NW, WASHINGTON, DC, 20037-1526
NUMBER OF CLAIMS: 57
EXEMPLARY CLAIM: 1
LINE COUNT: 1056
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An antidepressant or a pharmaceutically acceptable salt thereof, and an opiate antagonist or a pharmaceutically acceptable salt thereof, are used to treat refractory depression characterized by dissociation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **16590-41-3**, Naltrexone
(opiate antagonist and antidepressant for treatment of refractory depression with dissociation)
RN 16590-41-3 USPATFULL
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- (CA INDEX NAME)

Absolute stereochemistry.



IT **34911-55-2**, Bupropion SR
(opiate antagonist and antidepressant for treatment of refractory depression with dissociation)
RN 34911-55-2 USPATFULL
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



L17 ANSWER 12 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2004:261970 USPATFULL
TITLE: Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
INVENTOR(S): Briggs, Michael, Shrewsbury, MA, UNITED STATES
Hauser, Scott, St. Louis, MO, UNITED STATES
Ornberg, Richard, Hayward, CA, UNITED STATES
Koki, Alane, Marseille, FRANCE
PATENT ASSIGNEE(S): Pharmacia Corporation, Chesterfield, MO (U.S. corporation)

NUMBER	KIND	DATE

PATENT INFORMATION: US 2004204472 A1 20041014
APPLICATION INFO.: US 2004-773019 A1 20040205 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-451885P	20030304 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Charles E. Dunlap, P.O. Box 11070, Columbia, SC, 29211-1070
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 5174
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for preventing or treating obesity and obesity-related complications in a subject involves a monotherapy with a Cox-2 inhibitor or a combination therapy with a Cox-2 inhibitor and a conventional weight-loss agent. Also described are therapeutic compositions comprising a Cox-2 inhibitor and a conventional weight-loss agent. Pharmaceutical compositions and kits for implementing the present method are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **16590-41-3**, Naltrexone **34911-55-2**, Bupropion
(treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents)
RN 16590-41-3 USPATFULL
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 USPATFULL
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



L17 ANSWER 13 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2003:127681 USPATFULL
TITLE: Treatment of refractory depression with an opiate antagonist and an antidepressant

INVENTOR(S): Glover, Hillel, New York, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003087896	A1	20030508
APPLICATION INFO.:	US 2001-925190	A1	20010809 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DICKSTEIN SHAPIRO MORIN & OSHINSKY LLP, 2101 L STREET NW, WASHINGTON, DC, 20037-1526
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 714
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An antidepressant or a pharmaceutically acceptable salt thereof, and an opiate antagonist or a pharmaceutically acceptable salt thereof, are used to treat refractory depression characterized by dissociation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **34911-55-2**, Bupropion SR
(as antidepressant; refractory depression treatment with opiate antagonist and antidepressant)
RN 34911-55-2 USPATFULL
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



IT **16590-41-3**, Naltrexone
(as opiate antagonist; refractory depression treatment with opiate antagonist and antidepressant)
RN 16590-41-3 USPATFULL
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 14 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2001:173165 USPATFULL
TITLE: Methods and pharmaceutical compositions employing desmethylselegiline
INVENTOR(S): DiSanto, Anthony R., Gobles, MI, United States

	Blume, Cheryl D., Tampa, FL, United States(4)
PATENT ASSIGNEE(S):	Somerset Pharmaceuticals, Inc., Tampa, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6299901	B1	20011009
APPLICATION INFO.:	US 1999-262845		19990305 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-679330, filed on 12 Jul 1996 Continuation-in-part of Ser. No. WO 1996-US1561, filed on 11 Jan 1996 Continuation-in-part of Ser. No. US 1995-372139, filed on 13 Jan 1995

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-1979P	19950731 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Jones, Dameron L.
LEGAL REPRESENTATIVE: Vinson & Elkins LLP
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Figure(s); 17 Drawing Page(s)
LINE COUNT: 1573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The application is directed to the treatment of one or more symptoms associated with drug withdrawal by administering desmethylselegiline.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **34911-55-2**, Bupropion
(desmethylselegiline for treating drug withdrawal-associated symptoms)
RN 34911-55-2 USPATFULL
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



IT **16590-41-3**, Naltrexone
(desmethylselegiline for treating drug withdrawal-associated symptoms)
RN 16590-41-3 USPATFULL
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 15 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2005:287501 USPATFULL
TITLE: Use of N-desmethylclozapine to treat human neuropsychiatric disease
INVENTOR(S): Weiner, David M., San Diego, CA, UNITED STATES
Brann, Mark R., Del Mar, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005250767	A1	20051110
APPLICATION INFO.:	US 2005-98892	A1	20050404 (11)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2004-913117, filed on 5 Aug 2004, PENDING Continuation-in-part of Ser. No. US 2004-761787, filed on 21 Jan 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-442690P	20030123 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614, US
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 2415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed herein is a method to treat neuropsychiatric diseases including psychosis, affective disorders, dementia, neuropathic pain, and glaucoma. Treatment is carried out by administering a therapeutically effective amount of N-desmethylclozapine to a patient suffering from a neuropsychiatric disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **16590-41-3**, Naltrexone **34911-55-2**, Bupropion
(use of desmethylclozapine to treat human neuropsychiatric disease)
RN 16590-41-3 USPATFULL
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 USPATFULL
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



L17 ANSWER 16 OF 17 USPATFULL on STN

ACCESSION NUMBER:	2005:99544 USPATFULL
TITLE:	Use of N-desmethylclozapine to treat human neuropsychiatric disease
INVENTOR(S):	Weiner, David M., San Diego, CA, UNITED STATES Brann, Mark R., Del Mar, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005085463	A1	20050421
APPLICATION INFO.:	US 2004-913117	A1	20040805 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2004-761787, filed on 21 Jan 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-442690P	20030123 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614, US
NUMBER OF CLAIMS:	21
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	9 Drawing Page(s)
LINE COUNT:	2145

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein is a method to treat neuropsychiatric diseases including psychosis, affective disorders, dementia, neuropathic pain, and glaucoma. Treatment is carried out by administering a therapeutically effective amount of N-desmethylclozapine to a patient suffering from a neuropsychiatric disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **16590-41-3**, Naltrexone **34911-55-2**, Bupropion
(use of N-desmethylclozapine to treat human neuropsychiatric disease)

RN 16590-41-3 USPATFULL

CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 USPATFULL
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



L17 ANSWER 17 OF 17 USPATFULL on STN

ACCESSION NUMBER:	2001:160986 USPATFULL		
TITLE:	Use of sulfamate derivatives for treating impulse control disorders		
INVENTOR(S):	McElroy, Susan L., Cincinnati, OH, United States		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001023254	A1	20010920
	US 6323236	B2	20011127
APPLICATION INFO.:	US 2000-506991	A1	20000218 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	FROST BROWN TODD, LLC, 2200 PNC CENTER, 201 E. FIFTH STREET, CINCINNATI, OH, 45202		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
LINE COUNT:	933		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Impulse Control Disorders (ICD's) are characterized by harmful behaviors performed in response to irresistible impulses. The essential feature of an ICD is the failure to resist an impulse, drive, or temptation and to perform an act that is harmful to the person or to others. The present invention comprises methods for the treatment or prevention of ICD's using a class of sulfâmates of the following formula: ##STR1##

wherein X is CH.sub.2 or oxygen, and R.sub.1, R.sub.2, R.sub.3, R4 and R.sub.5 are as herein defined. Further, pharmaceutical compositions containing a compound of formula (I) as well as methods for their use and intermediates form part of the present invention are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **16590-41-3**, Naltrexone **34911-55-2**, Bupropion
(sulfamate derivs. for treatment of impulse control disorders, and use with other agents)

RN 16590-41-3 USPATFULL
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 USPATFULL
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:11:35 ON 28 MAR 2007

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:11:46 ON 28 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 MAR 2007 HIGHEST RN 928296-91-7
DICTIONARY FILE UPDATES: 27 MAR 2007 HIGHEST RN 928296-91-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s naltrexone
L1 191 NALTREXONE

=> s naltrexone/ct
'CT' IS NOT A VALID FIELD CODE
L2 0 NALTREXONE/CT

=> s naltrexone/cn
L3 1 NALTREXONE/CN

=> s bupropion/cn
L4 1 BUPROPION/CN

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.30	15.51

FILE 'CAPLUS' ENTERED AT 09:12:22 ON 28 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Mar 2007 VOL 146 ISS 14
FILE LAST UPDATED: 27 Mar 2007 (20070327/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 <> or naltrexone?

SmartSELECT INITIATED
New TRANSFER and ANALYZE Commands Now Available
See HELP TRANSFER and HELP ANALYZE for Details

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.47	15.98

FILE 'REGISTRY' ENTERED AT 09:12:31 ON 28 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

SET SMARTSELECT ON
SET COMMAND COMPLETED

SEL L3 1-
L5 SEL L3 1- CHEM : 12 TERMS

SET SMARTSELECT OFF
SET COMMAND COMPLETED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.65	27.63

FILE 'CAPLUS' ENTERED AT 09:12:31 ON 28 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

S L5 OR NALTREXONE?

3904 NALTREXONE?
L7 4022 L6 OR NALTREXONE?

=> s l4 <> or bupropion?

SmartSELECT INITIATED
New TRANSFER and ANALYZE Commands Now Available
See HELP TRANSFER and HELP ANALYZE for Details

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION

```
FULL ESTIMATED COST                                    46.70       74.33

FILE 'REGISTRY' ENTERED AT 09:12:56 ON 28 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

SET SMARTSELECT ON
SET COMMAND COMPLETED

SEL L4 1-
L8          SEL L4 1- CHEM :       8 TERMS

SET SMARTSELECT OFF
SET COMMAND COMPLETED


COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      11.65      85.98

FILE 'CAPLUS' ENTERED AT 09:12:57 ON 28 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

S L8 OR BUPROPION?


          1353 BUPROPION?
L10       1394 L9 OR BUPROPION?

=> s l9 and l10
L11       1392 L9 AND L10

=> d his

     (FILE 'HOME' ENTERED AT 09:11:35 ON 28 MAR 2007)

     FILE 'REGISTRY' ENTERED AT 09:11:46 ON 28 MAR 2007
L1          191 S NALTREXONE
L2            0 S NALTREXONE/CT
L3            1 S NALTREXONE/CN
L4            1 S BUPROPION/CN

     FILE 'CAPLUS' ENTERED AT 09:12:22 ON 28 MAR 2007

     FILE 'REGISTRY' ENTERED AT 09:12:31 ON 28 MAR 2007
                SET SMARTSELECT ON
L5           SEL L3 1- CHEM :      12 TERMS
                SET SMARTSELECT OFF

     FILE 'CAPLUS' ENTERED AT 09:12:31 ON 28 MAR 2007
L6         4022 S L5
L7         4022 S L6 OR NALTREXONE?

     FILE 'REGISTRY' ENTERED AT 09:12:56 ON 28 MAR 2007
                SET SMARTSELECT ON
L8           SEL L4 1- CHEM :       8 TERMS
                SET SMARTSELECT OFF

     FILE 'CAPLUS' ENTERED AT 09:12:57 ON 28 MAR 2007
L9         1392 S L8
L10        1394 S L9 OR BUPROPION?
```

```
L11         1392 S L9 AND L10

=> s l10 and l7
L12           51 L10 AND L7

=> s l12 and (extended? or controlled or slow release or long acting or
slow-released or long-acting)
         253679 EXTENDED?
         554221 CONTROLLED
              1 CONTROLLEDS
         554221 CONTROLLED
                  (CONTROLLED OR CONTROLLEDS)
         228598 SLOW
           7403 SLOWS
         235338 SLOW
                  (SLOW OR SLOWS)
         488279 RELEASE
          24436 RELEASES
         502938 RELEASE
                  (RELEASE OR RELEASES)
           8512 SLOW RELEASE
                  (SLOW(W)RELEASE)
         781774 LONG
             23 LONGS
         781795 LONG
                  (LONG OR LONGS)
         113830 ACTING
              5 ACTINGS
         113835 ACTING
                  (ACTING OR ACTINGS)
           7480 LONG ACTING
                  (LONG(W)ACTING)
         228598 SLOW
           7403 SLOWS
         235338 SLOW
                  (SLOW OR SLOWS)
         178343 RELEASED
            106 SLOW-RELEASED
                  (SLOW(W)RELEASED)
         781774 LONG
             23 LONGS
         781795 LONG
                  (LONG OR LONGS)
         113830 ACTING
              5 ACTINGS
         113835 ACTING
                  (ACTING OR ACTINGS)
           7480 LONG-ACTING
                  (LONG(W)ACTING)
L13            5 L12 AND (EXTENDED? OR CONTROLLED OR SLOW RELEASE OR LONG ACTING
                  OR SLOW-RELEASED OR LONG-ACTING)

=> focus
PROCESSING COMPLETED FOR L13
L14            5 FOCUS L13 1-

=> d ibib abs hitstr 1-5

L14  ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         1993:45784  CAPLUS
DOCUMENT NUMBER:          118:45784
TITLE:                    A controlled, sustained-release delivery
                          system for treating drug dependency
INVENTOR(S):              Kitchell, Judith P.; Muni, Indu A.; Boyer, Yvonne N.
```

PATENT ASSIGNEE(S): Dynagen, Inc., USA
SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9219226	A1	19921112	WO 1992-US3859	19920507
W: AU, CA, FI, HU, JP, KR, NO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
CA 2102507	A1	19921108	CA 1992-2102507	19920507
AU 9221548	A	19921221	AU 1992-21548	19920507
HU 69390	A2	19950928	HU 1993-3146	19920507
US 5486362	A	19960123	US 1993-140280	19931021
PRIORITY APPLN. INFO.:			US 1991-696637 A	19910507
			US 1992-880959 B1	19920507
			WO 1992-US3859 A	19920507

AB A drug delivery system useful in treating an individual for drug dependence is described. One embodiment of the system is useful for aiding individuals in the cessation of smoking or chewing nicotine-containing products. The delivery system includes a phys. constraint modulation system (PCMS) containing lobeline (I). The drug delivery system is capable of delivering I to an individual in a **controlled**, sustained-release manner and providing long-term therapeutic levels of I to the individual. The delivery of I in such a manner reduces or eliminates the individual's smoking or chewing habit. The PCMS may be a biodegradable polymer containing the I capable of s.c. or i.m. injection or implantation into the individual or may be a part of a transdermal patch containing I. Also described are methods of using the drug delivery systems in treating other drug dependencies and kits containing the drug delivery systems. A suspension formulation for s.c. administration was prepared which included lactic acid-glycolic acid copolymer microparticles containing 35 weight% I. In tests with volunteers, the formulation substantially decreased the number of cigarettes smoked.

IT **34911-55-2, Amfebutamone**
RL: BIOL (Biological study)
(drug delivery system containing, for cocaine dependence treatment)
RN 34911-55-2 CAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



IT **16590-41-3, Naltrexone**
RL: BIOL (Biological study)
(drug delivery system containing, for heroin dependence treatment)
RN 16590-41-3 CAPLUS
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:197273 CAPLUS
DOCUMENT NUMBER: 136:379380
TITLE: Drug addiction. Part III. Pharmacotherapy of addiction
AUTHOR(S): Vetulani, Jerzy
CORPORATE SOURCE: Institute of Pharmacology, Polish Academy of Sciences, Krakow, PL-31-343, Pol.
SOURCE: Polish Journal of Pharmacology (2001), 53(5), 415-434
CODEN: PJPAE3; ISSN: 1230-6002
PUBLISHER: Polish Academy of Sciences, Institute of Pharmacology
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. The last decade brought a considerable progress in pharmacotherapy of addiction. Basing on recently gained knowledge of mechanisms of development of addiction and the physiol. of the brain reward system, several therapeutic strategies have evolved. The strategies aimed at targeting the basic mechanisms of addiction rely on the premises that addiction is caused by adaptive changes in the central nervous system and that craving, which is the main cause of relapse, depends on dopaminergic mechanisms and requires high general excitability. The pharmacol. approach involves drugs that reduce neuronal adaptability by inhibiting the calcium entry to neurons both through voltage-gated channels (e.g. nimodipine) and NMDA receptors (e.g. memantine), and drugs that stimulate the inhibitory GABAergic system (γ-vinyl-GABA, baclofen). Particular attention is paid to the compds. that may attenuate dopaminergic hyperactivity, without considerable suppression of tonic activity of dopaminergic neurons (e.g. BP 897, a partial dopamine D3 receptor antagonist). Specific strategies are aimed at interference with the action of particular drugs of addiction. An important group includes the agonistic therapies (known also as substitution or maintenance therapies) in which a **long-acting** agonist is used in order to reduce the action of the drugs of high addictive potential (e.g. methadone against heroin addiction or vanoxerine (GBR 12909) against psychostimulants). Other specific strategies aimed at reduction of the transport of mols. of addictive substances into the brain: the approaches involve preparation of antibodies that form complexes unable to cross blood-brain barrier or enzymes accelerating the metabolism of the compds. in the blood (e.g. variants of butyrylcholinesterase). A considerable progress has been made in combating the abuse of legal addictive substances, alc. (**naltrexone**, acamprosate) and tobacco (**bupropion**). The prospects for developing effective pharmacotherapies against addiction are bright. Unfortunately, ideol. and social implications, as well as the conflict of interest with illegal narcotic manufacturers and distributors, may considerably hamper the progress in combating addiction (e.g. difficulties in introduction of methadone).

IT **16590-41-3, Naltrexone 34911-55-2, Bupropion**
RL: DMA (Drug mechanism of action); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmacotherapy of drug addiction)
RN 16590-41-3 CAPLUS
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 CAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 155 THERE ARE 155 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:545488 CAPLUS
DOCUMENT NUMBER: 135:117246
TITLE: Methods using a μ opioid antagonist, calcium channel blocker, and NMDA glutamate receptor modulator for the treatment of substance abuse
INVENTOR(S): Shulman, Albert
PATENT ASSIGNEE(S): Australia
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001052851	A1	20010726	WO 2001-AU60	20010122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				

BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2397726	A1	20010726	CA 2001-2397726		20010122
AU 2001026574	A5	20010731	AU 2001-26574		20010122
EP 1250136	A1	20021023	EP 2001-901062		20010122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2003520234	T	20030702	JP 2001-552898		20010122
NO 2002003482	A	20020919	NO 2002-3482		20020722
ZA 2002005839	A	20030722	ZA 2002-5839		20020722
US 2003144271	A1	20030731	US 2002-181990		20021106
PRIORITY APPLN. INFO.:			GB 2000-1390	A	20000122
			GB 2000-1647	A	20000126
			AU 2000-2237	A	20001221
			AU 2000-22370	A	20001221
			WO 2001-AU60	W	20010122

AB Methods are provided for therapy for substance (e.g. alc.) addiction which comprise the administration of a combination of (i) a μ-opioid receptor antagonist; (ii) a calcium channel blocker which is **long-acting** or in sustained-release form or which is nimodipine in rapid release form; and (iii) an NMDA glutamate receptor modulator. Also provided are combinations, kits and compns. useful therefor.

IT **16590-41-3, Naltrexone 34911-55-2, Bupropion**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(μ opioid antagonist, calcium channel blocker, and NMDA glutamate receptor modulator for treatment of substance abuse)

RN 16590-41-3 CAPLUS
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 CAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:83392 CAPLUS
DOCUMENT NUMBER: 146:163111
TITLE: Pyrazolines as antiaddictive agents ad their preparation, and pharmaceutical active substance combination
INVENTOR(S): Buschmann, Helmut H.
PATENT ASSIGNEE(S): Laboratorios del Dr. Esteve, S. A., Spain
SOURCE: PCT Int. Appl., 76pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007009691	A2	20070125	WO 2006-EP6965	20060715
WO 2007009691	A3	20070308		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1749525	A1	20070207	EP 2005-384009	20050715
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				

PRIORITY APPLN. INFO.: EP 2005-384009 A 20050715
US 2005-705483P P 20050805

OTHER SOURCE(S): MARPAT 146:163111
GI



AB The invention relates to an active substance combination comprising at least one substituted pyrazoline compound of formula I, and at least one

anti-addictive compound, a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination and the use of said active substance combination for the manufacture of a medicament. Compds. of formula I wherein R1 and R2 are independently (un)substituted Ph; R3 is (un)substituted (un)saturated (hetero)cyclyl, (un)substituted phenyl; and their stereoisomers, enantiomers, diastereoisomer, racemates, mixture of stereoisomer, mixture of diastereoisomers, mixture of enantiomers, pharmaceutically acceptable salts, solvates and N-oxides, thereof, are claimed. Example compound II was prepared by condensation of 4-chlorobenzaldehyde with Et pyruvate; the resulting trans-4-(4-chlorophenyl)-2-oxo-3-butenoic acid underwent cyclization with 2,4-dichlorophenylhydrazine hydrochloride to give 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydropyrazole-3-carboxylic acid, which underwent chlorination to give the corresponding acid chloride, which underwent amidation with 1-aminopiperidine to give compound II. All the invention compds. were evaluated for their CB1 and CB2 receptor affinity. From the assay, it was determined that compound II exhibited 93 % inhibition at 10-6 M concentration and a Ki value of < 25 nM against CB1, and 33 % inhibition (10-6 M) and > 1000 nM against CB2.

IT **16590-41-3, Naltrexone 34911-55-2, Bupropion**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; preparation of pyrazolines as antiaddictive agents and their active substance combination)

RN 16590-41-3 CAPLUS
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 CAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



L14 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1124114 CAPLUS
DOCUMENT NUMBER: 145:455030
TITLE: Preparation of substituted heteroaryl CB1 antagonists
INVENTOR(S): Yuan, Jun; Guo, Qin; Zhao, He; Hu, Shaojing;

Whitehouse, Darren; Fringle, Wallace; Mao, Jianmin; Maynard, George; Hammer, Jack; Wustrow, David; Li, Hongbin
PATENT ASSIGNEE(S): Neurogen Corporation, USA
SOURCE: PCT Int. Appl., 447pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006113704	A2	20061026	WO 2006-US14548	20060418
WO 2006113704	A3	20070208		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-672452P P 20050418
OTHER SOURCE(S): MARPAT 145:455030
GI



I



II

AB The title compds. I [A = CR1 or N; Ar1, Ar2 = (un)substituted 5-10 membered carbocycle and heterocycle; X = (un)substituted CH2, O, NH or SOmNH; m = 0-2; Y = (un)substituted alkylene; Z = (un)substituted OH, NH2, SOmNH2, etc.; R1 = H, halo, CN, etc.] which may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CB1 modulation in humans, domesticated companion animals and livestock animals, including appetite disorders, obesity and addictive disorders, were prepared E.g., a multi-step synthesis of II, starting from 2,6-dichloropyrazine and 4-(ethylamino)piperidine-4-

carboxamide, was given. Exemplified compds. I were tested at CB1 receptor. Thus, II as many other representative compds. I showed IC50 of 2 μM or less. Pharmaceutical compns. and methods for using compds. I to treat disorders responsive to CB1 modulation are provided, as are methods for using such ligands for receptor localization studies and various in vitro assays.

IT **16590-41-3, Naltrexone 34911-55-2, Bupropion**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of substituted heteroaryl compds. useful in treatment of diseases responsive to CB1 activation)

RN 16590-41-3 CAPLUS
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 CAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)